Figure 6
![Figure 6. IL-8 shows enhanced binding to purified heparan sulfate derived from Hs2st-deficient endothelial cells. [35S]Heparan sulfate purified from mutant or wild-type endothelial cells was incubated with biotinylated IL-8 and collected by streptavidin-conjugated magnetic beads. One set of samples was treated with K5 lyases before incubation with IL-8. IL-8 was not added in the control sample.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/120/8/10.1182_blood-2012-03-417139/4/zh89991295590006.jpeg?Expires=1735806305&Signature=iFNwllpnvcSws88n173AZohrBhCC3LoUE8r33sKBLTltW~wUkGHGpvVOwwYyBSIVbolj6j9rBKRUmpv5iTUzwiOQI9qr8ZytvdmFlKD9Mp2dIyLlNEos7aBA4AGwvY9mNOqH6f-JHutufQOuBSZDfGWeQTqINO~nDSA7XGzvHJkgY0z0JZivMjafDb-4A4c3il7WAhFf0UPsyuFnFp9VzOg~bF8EODWQ3Mt9bRQbOhvW4eV~ZnZa9cnnLgdfYIAHKoHP-J18QvSDTOjR8ad-JGA92BCcn5syM15Q0c3bbsdenEE2W33aKYHKbAAWeiesYsyhGbJ8QORrbnDYOyQsZw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
IL-8 shows enhanced binding to purified heparan sulfate derived from Hs2st-deficient endothelial cells. [35S]Heparan sulfate purified from mutant or wild-type endothelial cells was incubated with biotinylated IL-8 and collected by streptavidin-conjugated magnetic beads. One set of samples was treated with K5 lyases before incubation with IL-8. IL-8 was not added in the control sample.
